Connecting and Collaborating in Vienna

By Cheryl Selleny, Marketing and Communications

The 12th Annual Partnerships in Clinical Trials Congress is taking place November 19-21 in Vienna, Austria. The conference presents a great opportunity for networking and the exchange of ideas among industry colleagues. Over 150 speakers from pharmaceutical companies, CROs, and vendors will present various topics on clinical development. A few areas of discussion include: strategic partnerships, risked based monitoring, relationship management, and much more.

Bracket will be exhibiting at booth 241 to discuss our eClinical solutions.

Bracket Presents at CNS Summit 2013

By Cheryl Selleny, Marketing and Communications

CNS Summit 2013 kicked off this week in Boca Raton, Florida. The Summit offers a pre-competitive environment in which industry leaders can discuss the challenges being faced in CNS research and work together to find practical solutions.

Bracket’s subject matter experts will be presenting the below scientific posters. Check back after the conference to view the posters on our site.

Regional Baseline Symptom Patterns in Major Depressive Disorder Trials
Joan Busner, Ph.D. and Stuart A. Montgomery, M.D.

What PANSS Items Are Hardest To Rate: Observations From Global Studies
David G. Daniel, M.D. and Jean Dries, R.N., M.S.N.

What are the Optimal Cognitive Outcomes for Trials in Preclinical Alzheimer’s Disease?
Keith A. Wesnes, Ph.D.

Analysis of Family History Subgroups on Drug Placebo Separation and Placebo Response in a Positive Pivotal MDD Study of Levmomilnacipran
Dan DeBonis and Gary Sachs, M.D.

Bracket Presents at CTAD 2013

By Cheryl Selleny, Marketing and Communications

The  6th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference is taking place in sunny San Diego from November 14-16. The conference will cover every stage of clinical trials in AD and provide an opportunity for industry leaders to share innovative research with their peers.

See below for a list of our subject matter experts’ presentations taking place during the conference.

Poster Presentations
The poster presentations will be displayed throughout the conference.

P4: Selecting Acceptable Caregiver Informants for AD Clinical Trials: Is More Care Needed?
Priscilla Samuelson, RN and David S. Miller, MD, MA

Thursday, November 14th

Symposium 1

9:15 – 10:30am
Clinical trials in early stage Alzheimer’s disease: Current methodological and regulatory considerations
Moderator: John Harrison PhD, Metis Cognition Ltd, Kilmington Common, Wiltshire, UK
Communications:

  1. What are we trying to measure in preclinical and prodromal Alzheimer’s disease?
    Lon Schneider MD, MS. Keck School of Medicine of the University of Southern California, USA
  2. How can changes in cognitive function be measured in therapeutic trials in preclinical AD?
    Keith Wesnes PhD, Bracket Global, Goring UK & Swinburne University, Melbourne, Australia
  3. A regulatory perspective on therapeutic trials in early stage Alzheimer’s disease
    Nicholas Kozauer MD, Food and Drug Administration, Silver Spring, MD, USA

Oral Communications
California Ballroom AB: Data from Clinical Trials

11:15 – 11:30am
OC 2: Improvements to attention and verbal episodic memory with memantine in Parkinson’s disease dementia and dementia with Lewy bodies
Keith A. Wesnes, Dag Aarsland, Clive Ballard, Elisabet Londos

12:15 – 12:30pm
OC6: Evidence that compromised neurogenesis in Alzheimer’s disease is linked to APOE ϵ4 status and CSF Aß42
Keith A. Wesnes PhD, Peter Annas PhD, Hans Basun MD PhD, Kaj Blennow MD PhD

Friday, November 15th

Oral Communications
Ballroom C: Treatment Assessment for Clinical Trials

2:00 – 2:15 pm
OC39: Safety and efficacy of ORM-12741 on cognitive and behavioral symptoms in patients with Alzheimer’s disease: A randomized, double-blind, placebo-controlled, parallel group, multicenter, proof-of-concept 12 week study
K. Wesnes, J.O. Rinne, J. Hänninen, M. Murphy, H. Riordan, J. Rouru, and the ALPO Study Group